H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Unity Biotechnology (UBX) to $4 from $8 and keeps a Buy rating on the shares. The firm was “disappointed” to see the Phase 2B ASPIRE study of intravitreal foselutoclax in diabetic macular edema patients not meet the non-inferiority analysis specifically at the average of weeks 20 and 24, the analyst tells investors. However, the firm was “encouraged” that UBX1325 explicitly achieved non-inferiority to aflibercept for 9 out of 10 time points through 36 weeks and that UBX1325 patients gained 5.2 letters at week 24 and subsequently 5.5 letters at week 36, the analyst added.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.